Clinical trials: Neovascularization, Choroidal
Age Related Macular Degeneration
Usage of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00596388)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Notal Vision Ltd.
Age Related Macular Degeneration
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
The study purpose is to demonstrate that the target population can receive a packed FORESEE HOME unpack it, install and operate it to an extent that the FORESEE HOME can monitor them for changes in the visual field with good…
- Trial name
- UU2 (NCT00748384)
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration
Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)
To assess the CNV treatment effect of PDT with verteporfin in combination with IVTA using reduced fluence compared to the standard fluence.
- Trial name
- NCT00523406
- Testing
- Photodynamic therapy and intravitreal triamcinolone
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Epiretinal Membrane, Age Related Macular Degeneration
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
- Trial name
- NCT01846351
- Volunteers
- 16 people
- Sponsor
- New England Retina Associates
Age-related Macular Degeneration, Choroidal Neovascularization
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to…
- Trial name
- NCT00712491
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen Inc.
Age-Related Macular Degeneration, Choroidal Neovascularization
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related…
- Trial name
- EMERALD (NCT00766337)
- Testing
- Sirolimus in combination with ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Santen Inc.
Choroidal Neovascularization
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration.
- Trial name
- NCT00363168
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Age-Related Macular Degeneration
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
- Trial name
- NCT00725686
- Testing
- PF-04523655
- Where
- 11 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Quark Pharmaceuticals
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization…
- Trial name
- NCT01122511
- Testing
- 700 ug dexamethasone, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Allergan
Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to…
- Trial name
- NCT00775411
- Testing
- dexamethasone, ranibizumab
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 44 people
- Sponsor
- Allergan
Geographic Atrophy, Wet Macular Degeneration
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
To investigate pathomorphological and functional variations of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Chinese population using optical coherence tomography (OCT) to find which kinds of…
- Conditions
- Geographic Atrophy, Wet Macular Degeneration, Retinal Drusen
- Trial name
- NCT01666821
- Testing
- Follow-up observation
- Where
- China
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Age Related Macular Degeneration
Foresee Home for Monitoring Age Related Macular Degeneration (AMD)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with AMD.
- Trial name
- Foresee Home (NCT01010997)
- Testing
- Foresee Home
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Notal Vision Ltd.
Age-Related Macular Degeneration, Choroidal Vessels; Anastomosis
Evaluation of Optical Coherence Tomography.
Determination of the sensitivity and specificity of different combinations of imaging techniques (spectral domain optical coherence tomography, fundus photography and fluorescein angiography) used for the diagnosis of choroidal…
- Trial name
- ESSO (NCT01080898)
- Testing
- tests
- Volunteers
- 151 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Choroidal Neovascularization, Macular Degeneration
Photodynamic and Pharmacologic Treatment of CNV
The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration…
- Trial name
- PBS (NCT00570193)
- Testing
- verteporfin (Visudyne), ranibizumab (Lucentis)
- Volunteers
- 41 people
- Sponsor
- Mid-Atlantic Retina Consultations, Inc.
Choroidal Neovascularization
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group.
- Trial name
- PVD (NCT01256632)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vision Research Foundation
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Choroidal Neovascularization
Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum.
- Trial name
- NCT00510965
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration (AMD), Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established…
- Conditions
- Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)
- Trial name
- PERSPECTIVES (NCT00327470)
- Testing
- Pegaptanib Sodium 0.3 mg
- Where
- 58 sites in Austria, Belgium and 13 more
- Volunteers
- 288 people
- Sponsor
- Pfizer